% 0期刊文章%尼古拉斯Kayode Da Silva Soyombo %一个拉里萨巴蒂斯塔Xavier Emanuelle喇嘛罗查% %拉斐尔Arantes奥利维拉%罗德里戈·托雷斯% T生物标志物之间的鉴别诊断慢性创伤性脑病和阿尔茨海默病:系统回顾% D R 10.1212/01. wnl.0000801880.86213 2022%。aa % J首页神经病学% P S15-S16 % V 98% N 1补充1% X客观评估生物标志物的诊断效用能够区分慢性创伤性脑病(CTE)阿尔茨海默病(AD)。背景CTE是一种神经退行性疾病相关的多个头部创伤。诊断取决于neuropathologic发现后期,病人可有认知和行为的变化。这些症状通常可以被误认为是其他痴呆,如广告,导致低估CTE的频率。因此,特定的生物标志物可以有助于理解疾病的发展,诊断和预后。设计/方法系统地搜查了MEDLINE、Embase和Cochrane数据库。我们还搜查了试验注册和引用文章的列表。我们包括研究“微小”相关的问题和分析不同的生物标志物。我们筛选标题和摘要,如果他们是相关的,我们评估了全文故事体地和报告结果。22个研究结果被确定通过数据库搜索。一项研究被排除由于数据库之间的表里不一。21篇文章进行资格审核和6是包含在定性的合成。P-Tau和T-tau蛋白质被表示为生物标记的神经退行性疾病如CTE和广告,但不是从其他tauopathies。 Exosomal tau levels are higher in CTE patients than in AD patients, and it might be useful since it is very stable, crosses the blood–brain barrier and reflects their cellular origin. Pathophysiologic differences between CTE and AD are pointed out as a way to find specific biomarkers for CTE. The biomarkers associated with neuroaxonal damage (NFL), glial response with astroglial scarring (GFAP and sTREM2), and microvascular damage with disruption of the blood–brain barrier (cerebrospinal fluid/serum albumin ratio) are promising in that way.Conclusions Biomarkers that arise from pathophysiologic processes distinct from the 2 diseases, appear to be promising. However, further well-designed studies are needed to assess the real utility of the biomarkers in differential diagnosis between CTE and AD. %U //www.ez-admanager.com/content/neurology/98/1_Supplement_1/S15.3.full.pdf